

# Ludovic Martinet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2810427/publications.pdf>

Version: 2024-02-01

37  
papers

3,775  
citations

236925

25  
h-index

345221

36  
g-index

39  
all docs

39  
docs citations

39  
times ranked

5545  
citing authors

#	ARTICLE	IF	CITATIONS
1	The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. <i>Nature Immunology</i> , 2014, 15, 431-438.	14.5	410
2	Balancing natural killer cell activation through paired receptors. <i>Nature Reviews Immunology</i> , 2015, 15, 243-254.	22.7	410
3	Human Solid Tumors Contain High Endothelial Venues: Association with T- and B-Lymphocyte Infiltration and Favorable Prognosis in Breast Cancer. <i>Cancer Research</i> , 2011, 71, 5678-5687.	0.9	386
4	Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 446-459.	9.4	198
5	TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma. <i>Blood</i> , 2018, 132, 1689-1694.	1.4	198
6	Molecular mechanisms of natural killer cell activation in response to cellular stress. <i>Cell Death and Differentiation</i> , 2014, 21, 5-14.	11.2	163
7	Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment. <i>Cancer Cell</i> , 2018, 33, 634-648.e5.	16.8	163
8	High endothelial venules (HEVs) in human melanoma lesions. <i>Oncotarget</i> , 2012, 1, 829-839.	4.6	161
9	Design of phosphorylated dendritic architectures to promote human monocyte activation. <i>FASEB Journal</i> , 2006, 20, 2339-2351.	0.5	132
10	High Endothelial Venule Blood Vessels for Tumor-Infiltrating Lymphocytes Are Associated with Lymphotoxin $\alpha$ -Producing Dendritic Cells in Human Breast Cancer. <i>Journal of Immunology</i> , 2013, 191, 2001-2008.	0.8	123
11	DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. <i>Immunology and Cell Biology</i> , 2014, 92, 237-244.	2.3	115
12	Immunosurveillance and therapy of multiple myeloma are CD226 dependent. <i>Journal of Clinical Investigation</i> , 2015, 125, 2077-2089.	8.2	111
13	DNAM-1 Expression Marks an Alternative Program of NK Cell Maturation. <i>Cell Reports</i> , 2015, 11, 85-97.	6.4	111
14	PGE2 inhibits natural killer and $\gamma\delta$ T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. <i>Biochemical Pharmacology</i> , 2010, 80, 838-845.	4.4	108
15	Stimulated $\gamma\delta$ T Cells Increase the In Vivo Efficacy of Trastuzumab in HER-2+ Breast Cancer. <i>Journal of Immunology</i> , 2011, 187, 1031-1038.	0.8	99
16	Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma. <i>Cancer Research</i> , 2014, 74, 7298-7308.	0.9	96
17	Anti-inflammatory and immunosuppressive activation of human monocytes by a bioactive dendrimer. <i>Journal of Leukocyte Biology</i> , 2009, 85, 553-562.	3.3	89
18	A regulatory cross-talk between $\gamma\delta$ T lymphocytes and mesenchymal stem cells. <i>European Journal of Immunology</i> , 2009, 39, 752-762.	2.9	85

#	ARTICLE	IF	CITATIONS
19	Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy. <i>Immunity</i> , 2020, 53, 824-839.e10.	14.3	85
20	Cancer immunoediting and immune dysregulation in multiple myeloma. <i>Blood</i> , 2020, 136, 2731-2740.	1.4	84
21	NK cells require IL-28R for optimal in vivo activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2376-84.	7.1	82
22	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells. <i>Immunity</i> , 2020, 53, 805-823.e15.	14.3	79
23	Tumor high endothelial venules (HEVs) predict lymphocyte infiltration and favorable prognosis in breast cancer. <i>OncImmunology</i> , 2012, 1, 789-790.	4.6	39
24	Pitfalls on the roadmap to T cell-based cancer immunotherapies. <i>Immunology Letters</i> , 2009, 124, 1-8.	2.5	35
25	Hospicells derived from ovarian cancer stroma inhibit T cell immune responses. <i>International Journal of Cancer</i> , 2010, 126, 2143-2152.	5.1	25
26	Phosphoantigens Overcome Human TCRV $\beta$ 9+T $\beta$ 7 Cell Immunosuppression by TGF- $\beta$ 2: Relevance for Cancer Immunotherapy. <i>Journal of Immunology</i> , 2010, 184, 6680-6687.	0.8	25
27	Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions. <i>Blood Advances</i> , 2019, 3, 1681-1694.	5.2	24
28	DNAM-1: would the real natural killer cell please stand up!. <i>Oncotarget</i> , 2015, 6, 28537-28538.	1.8	23
29	Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model. <i>JCI Insight</i> , 2019, 4, .	5.0	20
30	How tumors might withstand T-cell attack. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 2433-2442.	5.4	19
31	Regulation of tumor-associated high-endothelial venules by dendritic cells. <i>OncImmunology</i> , 2013, 2, e26470.	4.6	12
32	SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma. <i>Blood</i> , 2022, 139, 1160-1176.	1.4	11
33	Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth. <i>Blood Advances</i> , 2022, 6, 672-678.	5.2	8
34	Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3854.	4.1	7
35	Natural Killer cell control of BRAFV600E mutant melanoma during targeted therapy. <i>OncImmunology</i> , 2015, 4, e998119.	4.6	5
36	Regulation of Immune Cell Functions through Nectin and Nectin-Like Receptors. , 2016, , 404-414.		4

#	ARTICLE	IF	CITATIONS
37	Abstract B155: Anti-CD137 mAb therapy of multiple myeloma. , 2016, , .		0